This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Not All Treatments Are Equal!

M. Brian Fennerty, MD; Richard E. Sampliner, MD

Arch Intern Med. 1991;151(12):2365-2366.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In this issue of the ARCHIVES, Sabesin et al¹ report on the efficacy of famotidine twice-daily (BID) vs nocturnal therapy vs placebo in controlling the symptoms of gastroesophageal reflux disease (GERD) and in healing reflux esophagitis. The authors demonstrate that dosing BID is more effective than the other regimens in relieving daytime heartburn and results in greater symptom relief as manifested by reduced antacid consumption. The authors also conclude that while both doses of famotidine were more effective than placebo in relief of reflux symptoms and healing erosive esophagitis, the BID dose results in better symptom control. The proposed mechanism of this improvement seen with BID dosing was thought to be better 24-hour pH control of esophageal acid exposure time. Although the authors conclude that famotidine is effective in relieving symptoms of GERD and in healing esophagitis, only about half of the patients were symptom free or healed at . . . [Full Text PDF of this Article]

Author Affiliations
Section of Gastroenterology Department of Medicine University of Arizona Medical Center Tucson, AZ 85724

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?